In the most recent quarter, billionaire John Paulson, the president and portfolio manager of hedge fund Paulson & Co, made several key changes …
Late last week, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced the FDA approval of its lead drug Trulance (plecanatide) for the treatment of adults with …
BTIG analyst Tim Chiang weighed in today on Synergy Pharmaceuticals Inc (NASDAQ:SGYP), after the drug maker reported the achievement of a milestone few biotechnology companies reach—FDA …
Yesterday after the close, the FDA granted final approval to Synergy Pharmaceuticals Inc’s (NASDAQ:SGYP) Trulance (plecanatide), for the treatment of chronic constipation. However, Synergy …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) impressed Rodman & Renshaw analyst Ram Selvaraju with the announcement yesterday evening that the biotech has attained “a milestone …
Canaccord analyst John Newman was out pounding the table on Synergy Pharmaceuticals Inc (NASDAQ:SGYP) Friday, reiterating a Buy rating and $13 price target, which represents …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced that the U.S.
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) investors are eagerly awaiting the FDA’s decision on plecanatide’s (for the treatment of chronic idiopathic constipation) new drug application, which should …
Canaccord analyst John Newman is out today with a favorable research report on Synergy Pharmaceuticals Inc (NASDAQ:SGYP) after the firm’s competition, Phase 3 …
After market-close yesterday, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) released positive second Phase 3 results for plecanatide, the firm’s pipeline daily pill designed to treat …
